BACKGROUND: Quantitative spectral analysis of the radiofrequency (RF) signals that underlie grayscale EUS images can be used to provide additional, objective information about tissue state. OBJECTIVE: Our purpose was to validate RF spectral analysis as a method to distinguish between (1) benign and malignant lymph nodes and (2) normal pancreas, chronic pancreatitis, and pancreatic cancer. DESIGN AND SETTING: A prospective validation study of eligible patients was conducted to compare with pilot study RF data. PATIENTS: Forty-three patients underwent EUS of the esophagus, stomach, pancreas, and surrounding intra-abdominal and mediastinal lymph nodes (19 from a previous pilot study and 24 additional patients). MAIN OUTCOME MEASUREMENTS: Midband fit, slope, intercept, and correlation coefficient from a linear regression of the calibrated RF power spectra were determined. RESULTS: Discriminant analysis of mean pilot-study parameters was then performed to classify validation-study parameters. For benign versus malignant lymph nodes, midband fit and intercept (both with t test P < .058) provided classification with 67% accuracy and area under the receiver operating curve (AUC) of 0.86. For diseased versus normal pancreas, midband fit and correlation coefficient (both with analysis of variance P < .001) provided 93% accuracy and an AUC of 0.98. For pancreatic cancer versus chronic pancreatitis, the same parameters provided 77% accuracy and an AUC of 0.89. Results improved further when classification was performed with all data. LIMITATIONS: Moderate sample size and spatial averaging inherent to the technique. CONCLUSIONS: This study confirms that mean spectral parameters provide a noninvasive method to quantitatively discriminate benign and malignant lymph nodes as well as normal and diseased pancreas. 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
BACKGROUND: Quantitative spectral analysis of the radiofrequency (RF) signals that underlie grayscale EUS images can be used to provide additional, objective information about tissue state. OBJECTIVE: Our purpose was to validate RF spectral analysis as a method to distinguish between (1) benign and malignant lymph nodes and (2) normal pancreas, chronic pancreatitis, and pancreatic cancer. DESIGN AND SETTING: A prospective validation study of eligible patients was conducted to compare with pilot study RF data. PATIENTS: Forty-three patients underwent EUS of the esophagus, stomach, pancreas, and surrounding intra-abdominal and mediastinal lymph nodes (19 from a previous pilot study and 24 additional patients). MAIN OUTCOME MEASUREMENTS: Midband fit, slope, intercept, and correlation coefficient from a linear regression of the calibrated RF power spectra were determined. RESULTS: Discriminant analysis of mean pilot-study parameters was then performed to classify validation-study parameters. For benign versus malignant lymph nodes, midband fit and intercept (both with t test P < .058) provided classification with 67% accuracy and area under the receiver operating curve (AUC) of 0.86. For diseased versus normal pancreas, midband fit and correlation coefficient (both with analysis of variance P < .001) provided 93% accuracy and an AUC of 0.98. For pancreatic cancer versus chronic pancreatitis, the same parameters provided 77% accuracy and an AUC of 0.89. Results improved further when classification was performed with all data. LIMITATIONS: Moderate sample size and spatial averaging inherent to the technique. CONCLUSIONS: This study confirms that mean spectral parameters provide a noninvasive method to quantitatively discriminate benign and malignant lymph nodes as well as normal and diseased pancreas. 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
Authors: R M Golub; R E Parsons; B Sigel; E J Feleppa; J Justin; H A Zaren; M Rorke; J Sokil-Melgar; H Kimitsuki Journal: J Ultrasound Med Date: 1993-10 Impact factor: 2.153
Authors: John Dewitt; Benedict M Devereaux; Glen A Lehman; Stuart Sherman; Thomas F Imperiale Journal: Clin Gastroenterol Hepatol Date: 2006-05-03 Impact factor: 11.382
Authors: M F Catalano; E Alcocer; A Chak; C C Nguyen; I Raijman; J E Geenen; S Lahoti; M V Sivak Journal: Gastrointest Endosc Date: 1999-09 Impact factor: 9.427
Authors: T Tateishi; J Machi; E J Feleppa; R Oishi; J Jucha; E Yanagihara; L J McCarthy; T Noritomi; K Shirouzu Journal: Ultrasound Med Biol Date: 1998-10 Impact factor: 2.998
Authors: Ronald E Kumon; Kayode Olowe; Ashley L Faulx; Farees T Farooq; Victor K Chen; Yun Zhou; Richard C K Wong; Gerard A Isenberg; Michael V Sivak; Amitabh Chak; Cheri X Deng Journal: Gastrointest Endosc Date: 2007-10-29 Impact factor: 9.427
Authors: R E Kumon; A Repaka; M Atkinson; A L Faulx; R C K Wong; G A Isenberg; Y-S Hsiao; M S R Gudur; C X Deng; A Chak Journal: Endoscopy Date: 2012-05-25 Impact factor: 10.093
Authors: Ronald E Kumon; Aparna Repaka; Matthew Atkinson; Ashley L Faulx; Richard C K Wong; Gerard A Isenberg; Yi-Sing Hsiao; Madhu S R Gudur; Cheri X Deng; Amitabh Chak Journal: Gastrointest Endosc Date: 2012-04-11 Impact factor: 9.427
Authors: Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2017-04-17
Authors: Grace G Bushnell; Xiaowei Hong; Rachel M Hartfield; Yining Zhang; Robert S Oakes; Shreyas S Rao; Jacqueline S Jeruss; Jan P Stegemann; Cheri X Deng; Lonnie D Shea Journal: Ann Biomed Eng Date: 2019-09-23 Impact factor: 3.934